Vimarsana
Biggest News Aggregation in the World

Brennan Doyle News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Brennan Doyle. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Brennan Doyle Today - Breaking & Trending Today

BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer's Dementia -April 10, 2024 at 07:01 am EDT - Vimarsana News

BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer's Dementia -April 10, 2024 at 07:01 am EDT

Company plans to initiate trial following recent meeting with FDA No FDA-approved therapies for acute treatment of AAD are currently available NEW HAVEN, Conn., April 10, 2024 -- BioXcel...

BioXcel Therapeutics Announces Termination of Proposed Public Offering - Vimarsana News

BioXcel Therapeutics Announces Termination of Proposed Public Offering

NEW HAVEN, Conn., Feb. 13, 2024 -- BioXcel Therapeutics, Inc. , a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and...

A Glimpse of an Award-Winning Car Collection Few Have Seen - Vimarsana News

A Glimpse of an Award-Winning Car Collection Few Have Seen

Entrepreneur Jim Patterson gives Penta a tour of his private showroom in Louisville, Kentucky

BioXcel Therapeutics Receives Permanent J-Code for IGALMI™ (dexmedetomidine) Sublingual Film from Centers for Medicare & Medicaid Services - Vimarsana News

BioXcel Therapeutics Receives Permanent J-Code for IGALMI™ (dexmedetomidine) Sublingual Film from Centers for Medicare & Medicaid Services

Standardizes and improves product reimbursement process New HCPCS Level II code J1105 to be effective January 1, 2024 NEW HAVEN, Conn., Oct. 30, 2023 -- BioXcel Therapeutics, Inc. , a...

BioXcel Therapeutics Provides Update on Recent Developments for Late-Stage Clinical Programs and Expansion of IP Portfolio for IGALMI™ (dexmedetomidine) Sublingual Film - Vimarsana News

BioXcel Therapeutics Provides Update on Recent Developments for Late-Stage Clinical Programs and Expansion of IP Portfolio for IGALMI™ (dexmedetomidine) Sublingual Film

Meetings scheduled with FDA in October and November for TRANQUILITY and SERENITY III programs Company strengthens IGALMI™ market exclusivity through receipt of two Notices of Allowance ...